ERBB2 and cancer: Also EGFR/HER-2 inhibition by the dual inhibitor lapatinib resulted in enhanced radiosensitivity in cancer cells of various entities, such as bladder cancer, peripheral nerve sheath tumors, pancreatic or breast cancer.